Commercial Manufacturing of Autologous Muscle Derived Cell (AMDC) products
Challenge from the Client
Multiple challenges were presented for this effort. Primary challenges involved:
- Renovation of an existing manufacturing facility,
- Demonstrating that the facility, systems and equipment were fit for intended use for compliant commercial manufacturing operations through application of a comprehensive commissioning and qualification program.
- Providing program management, compliance, and project controls support for a multi-faceted, facility renovation project.
- Providing compliance, design, and project delivery consulting support to assist in transition from a capital project environment to CGMP-compliant commercial manufacturing operations for AMDC products.
- Providing SME-level analysis and evaluations of manufacturing processes, process tickets, and support systems to identify potential gaps & needs for transitioning current manufacturing operations from preclinical- and clinical-scale, to fully CGMP-compliant commercial manufacturing operations.
Our Approach & Solution
The IPS team applied expert industry knowledge and skills to deliver value to this effort. We provided coaching in many areas to help align procedures, templates, deliverables and activities with current industry practice and guidance.
The Results
This ongoing collection of projects will continue through multiple years. Projects include:
- Site CGMP and design assessments of the commercial manufacturing facility, systems and equipment and recommendations for remediation
- Laboratory commissioning
- Site CGMP assessment of the preclinical & clinical manufacturing facility, systems and equipment and recommendations for remediation
- Development of URS's, GMP impact assessments, and maintenance & calibration work instructions for production and lab equipment in the preclinical & clinical manufacturing facility
- Manufacturing Process Quality Risk Assessment
- Compliance support (Commissioning, Qualification, Validation) for the commercial manufacturing facility, involving 1250 documents and 450 test execution activities supporting:
- Building Management Systems
- Warehouse and Logistics areas
- Laboratories
- Manufacturing
- Facility and utilities
Related Molecules
Antibody Drug Conjugation Commercial Manufacturing
Read MoreApplied first class design tools and industry specific experiences to develop a greenfield site for commercial ADC manufacturing.
Annex 1 - The Brave New World of Aseptic Regulatory Compliance
Read MoreAfter six years in review, the final emergence of Annex 1 in August 2022 has either been a consolidation of accepted practice and wisdom, or a rude awakening for many!
Large-Scale Bulk Manufacturing Facility
Read MoreIPS built a new greenfield facility in Ireland for bulk biologics manufacturing with single-use technology under an extremely aggressive timeline.
Single-Use Mammalian Cell Culture Facility - Vial to Vial
Read MoreOur challenge was to design a biologics manufacturing launch facility within an existing shell & office building.
Fast-Track Project Delivery Model
Read MoreA vaccine manufacturer and distributor needed IPS’ expertise to meet an aggressive timeline for expansion of their production facility.
Detailed Process Piping
Read MoreSupporting a client’s dynamic business requirements to produce a near-fabrication-level model to reduce schedule time.
Water For Injection (WFI) Generation System Design for a Global CMO Biotechnology Facility for the Manufacture of mAb/Recombinant Protein
Read MoreBiotech CMO client needed an n+1 redundant system to handle increased WFI demand, while reducing operating costs.
Clinical Phage Production - Design/Build/Qualify
Read MoreA start-up biotech company needed to generate phase 1 and phase 2 clinical material for a phage-based therapy on an aggressive timeline and tight budget.
Largest Single-use Based mAb Facility in the World
Read MoreOur CMO client wanted to do something radically different by creating a multiproduct, multiscale mAb facility that could flex upstream capacity in 2000L intervals.
Mammalian Cell Culture to COVID-19 Vaccine Adjuvant in 3 weeks
Read MoreSoon after the COVID-19 outbreak, our client's direction shifted quickly from a mammalian cell culture facility to a COVID-19 vaccine adjuvant production facility.
Delivering a New Building with Two Project Teams
Read MoreProvided a client and building tenant with construction management services for the interior fit-out of a new 50,000sf pharmaceutical testing facility while a separate vendor constructs the core & shell for the landlord.
Gene Therapy Facility
Read MoreOur client needed an efficient design for their gene biologics plant within an existing building with limited space for air handlers and mechanical equipment.
Clinical CAR-T Capabilities
Read MoreA global biopharmaceutical manufacturer chose iCON to expedite its CAR-T therapy production timeline.
Clinical Lentivirus/AAV Manufacturing Facility
Read MoreA fast-tracked execution strategy for gene therapy manufacturing requiring “out of the box” thinking.
Site Selection for an Advanced Gene Therapy Company
Read MoreOur client was looking for a new site for their 2000L scale gene therapy manufacturing facility in a very saturated real estate market.
